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ABSTRACT
Type II testicular germ cell tumors (TGCTs) represent the most frequent 
malignancy in Caucasian males (20–40 years). Even if diagnosed with disseminated 
disease, >80% of patients are cured; however, a small percentage of cases 
progress and result in death. It is commonly accepted that these cancers arise 
from a disturbed testicular embryonic niche that leads to the block of gonocyte 
differentiation. The subsequent development of the invasive seminomas and non-
seminomas is due to a combination of genetic, epigenetic and microenvironment-
based alterations (genvironment). Hepatocyte growth factor (HGF) is present in the 
testicular microenvironment, together with its receptor c-MET, from early embryonic 
development to an adult stage. In addition, c-MET is a well-known proto-oncogene 
involved in the onset and progression of various human cancers. Herein, we have 
investigated the expression and availability of HGF and c-MET in TCam-2, NCCIT and 
NT2D1 cells, which are type II (T)GCT representative cell lines, and the effect of c-MET 
activation/repression on the regulation of cancerous biological processes. We found 
that NT2D1 cells increase their proliferation, polarized migration, and invasion in 
response to HGF administration. NCCIT cells respond to HGF stimulation only partially, 
whereas TCam-2 cells do not respond to HGF, at least according to the investigated 
parameters. Interestingly, the immunohistochemical study of c-MET distribution 
in TGCTs confirm its presence in both seminoma and non-seminoma lesions with 
different patterns. Notably, we found the highest c-MET immunoreactivity in the 
epithelial elements of the various components of TGCTs: teratoma, yolk sac tumor 
and choriocarcinoma.
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INTRODUCTION
Testicular germ cell tumors are a heterogeneous 
group of neoplasms with different histopathology and 
variable clinical course. Histologically and clinically, they 
are subdivided into type I (infants), type II (adolescents 
and young adults, i.e., TGCTs) and type III (elderly) 
[1, 2]. The incidence of type II, by definition malignant 
tumors (seminomas and non-seminomas), has drastically 
increased in the last decades [3]. They originate from a 
common precursor lesion, the germ cell neoplasia in situ 
(GCNIS), which arises from transformed primordial germ 
cells/gonocytes. The default development of this lesion 
leads to the formation of seminomas, whose cells present 
gonocyte-like features. A genetic reprogramming of these 
cells gives rise to embryonal carcinoma cells, the stem 
cells of non-seminomas, malignant tumors that mimic 
embryonic development, both with possible embryonic 
(teratomas) and extra-embryonic differentiation (yolk sac 
tumors and choriocarcinomas) [2, 4, 5]. These cancers are 
mainly characterized by a good prognosis, since they are 
extraordinarily chemo- and radio-sensitive. However, in 
a small percentage of cases, a cisplatin-resistance exists, 
making cure difficult. For this reason, TGCTs remain 
an important cause of mortality in young men. A deeper 
investigation of TGCT biology may allow an identification 
of novel biological therapies or novel predictive markers 
of an aggressive disease [6–8].
TGCTs are featured by low rates of somatic 
mutations, which is exceptional for solid cancers in 
adults [9–15]. Notwithstanding, these cancers present 
genetic alterations, such as a high frequency of chromatin 
rearrangement and chromosomal anomalies (among 
them, chromosome 12 alterations have been fully 
described) [16–20]. In addition, a gain of chromosome 
7, whose region 7q31 encodes the tyrosine kinase 
receptor c-MET, has been described in TGCTs [21]. 
However, no c-MET mutations have been reported so 
far in these cancers [22]. An alteration of the c-MET 
pathway has been reported in several cancer types [23–25] 
(www.vai.org/met). It has also been shown that treatment 
with c-MET selective inhibitors, in both in vitro and in 
vivo models, promotes a slow-down of tumor growth 
[26–28]. As a result, patients are currently recruited for 
Phase I, II and III anti-tumor clinical trials of these drugs 
(http://www.clinicaltrials.gov). The c-MET receptor 
binds to hepatocyte growth factor (HGF), a pleiotropic 
cytokine produced by mesenchymal cells, which acts on 
epithelial cells in a paracrine fashion [29–32]. The HGF/c-
MET interaction triggers c-MET receptor dimerization 
and tyrosine phosphorylation, thus modulating multiple 
biological processes, including proliferation, migration 
and invasion, morphogenesis and tubulogenesis, 
differentiation and apoptosis escape [33, 34]. Notably, all 
these phenomena occur not only in oncogenesis but also, 
physiologically, during embryogenesis and are necessary 
for the maintenance of adult tissue homeostasis as well. 
We previously demonstrated that HGF and its receptor 
c-MET are expressed and active in the testis from early 
embryonic development to an adult stage [35], influencing 
many activities of testicular somatic and germ cells, both 
in humans and in rodents [35–38]. It is worth highlighting 
that, the most accepted theory about the onset of this kind of 
tumors states that the gonocyte block of differentiation is due 
to a combination of genetic and epigenetic aberrations with 
micro-environmental cues that jointly lead to the disease [39, 
40]. This has led to coining a word, “genvironment”, which 
designates the close interaction between environmental 
factors, diffusible signals and gene expression regulation in 
the onset of TGCTs [41]. Intriguingly, in TGCT patients, 
an inverse correlation between progression-free survival 
and some circulating cytokines, including HGF, has been 
recently found [42]. In this respect, it is worth mentioning 
that c-MET availability has also been correlated with 
resistance to radio- and chemotherapy in different cancer 
types [43–45]. Altogether, these observations lead us to 
hypothesize that the deregulation of c-MET activation could 
represent one of the molecular mechanism responsible for 
the TGCT onset and/or progression.
Therefore, we have analyzed the expression 
pattern of the HGF/c-MET system and its possible role 
in pathogenesis of TGCTs. For this purpose, we used the 
seminoma cell line TCam-2, an intermediate-seminoma/
non-seminoma cell line NCCIT and an embryonal 
carcinoma cell line NT2D1 as experimental models. 
We evaluated biological responses to HGF, such as 
proliferation, migration and invasion. Next, we studied the 
immunoreactivity of c-MET in histological samples of all 
major variants of TGCTs, aiming to correlate clinical data 
with the data provided by an in vitro study.
RESULTS AND DISCUSSION
TGCT cell lines have different copy numbers of 
c-MET gene
As previously mentioned, the literature data report 
a gain of chromosome 7 in type II GCTs. Since c-MET 
gene is located in the ch7q31 region, we decided to 
use fluorescence in situ hybridization (FISH) analysis 
to assess if GCT cell lines gained the c-MET gene. As 
expected, the DAPI (4’,6-diamidino-2-phenylindole) 
images revealed the presence of global aneuploidy in 
all cell lines. Interphase and metaphase studies detected 
the presence of 2 signals of MET probe on two distinct 
chromosomes in NCCIT cells, and 3 signals on three 
distinct chromosomes in NT2D1 cells, whereas in TCam-2 
cells 4 different signals were found, including 2 on 
two distinct chromosomes and 2 on a single derivative 
chromosome (Figure 1A). The latter observation is in line 
with the already demonstrated tetraploid karyotype of 
TCam-2 cells [46].
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TGCT cell lines differentially express c-MET 
receptor
The c-MET gene expression level has been 
assayed by real-time PCR analysis. We found that 
TCam-2, NCCIT and NT2D1 cells express c-MET at 
different levels. Particularly, in agreement with the 
reported FISH analyses, TCam-2 cells express higher 
levels of c-MET mRNA compared with NCCIT and 
NT2D1 cells (Figure 1B, Supplementary Figure 5). 
To evaluate c-MET protein expression, we performed 
both western blotting and immunofluorescence assays. By 
western blot analysis, we detected a higher expression of 
full-length c-MET protein (145 kDa) in NT2D1 cell line 
compared with NCCIT cells and, surprisingly, even with 
TCam-2 cells (Figure 1C, Supplementary Figure 5). This 
observation is a strong indication of a post-transcriptional 
regulation of c-MET protein biosynthesis, which reinforces 
the already demonstrated notion that these cancers are 
regulated at the post-genomic level [47]. 
Immunofluorescence analysis by confocal 
microscopy, revealed that in all cell lines, c-MET protein 
appears localized, as expected, at the plasma membrane 
level, since c-MET is a membrane receptor. However, 
besides the plasma membrane localization, a cytoplasmic 
diffused signal is also detectable. It is tempting to 
speculate that the latter c-MET localization indicates, the 
presence of the immature receptor form in the endoplasmic 
reticulum and/or its localization in endosomal vesicles 
containing the recycled receptor. In both cases, this 
observation would suggest that a basal turnover of c-MET 
protein is present in all TGCT cell lines, even if further 
investigations are needed to confirm this hypothesis. It 
is worth highlighting that we observed a dual population 
in NCCIT cell line: one c-MET-positive (approximately 
the 68% of the whole population) and the other c-MET-
negative, which, reasonably, are differentially sensitive to 
receptor stimulation (Figure 1D).
TGCT cell lines do not express and secrete HGF
To assess if our cell lines express HGF mRNA, 
we performed RT-PCR experiments, which revealed 
that TCam-2, NCCIT and NT2D1 cell lines do not 
express HGF mRNA. Human colon fibroblasts were 
used as a positive control and SKOV-3 cells were used 
as a negative control for the expression of this gene, 
as shown in Figure 2A. To investigate the availability 
of HGF protein in TGCT cell lines and to evaluate the 
possibility of a cellular storage and subsequent secretion 
of this molecule, we also performed a scatter activity 
assay, which tested the ability of cultured cell-conditioned 
media to induce scatter of MDCK cell clusters. Human 
colon fibroblast-conditioned medium (not shown) or 
HGF added medium were used as positive controls. The 
scatter phenotype in MDCK cells was observed with 
human colon fibroblasts (positive control, not shown) and 
recombinant HGF-added media (Supplementary Figure 1), 
while conditioned media obtained from SKOV-3 (negative 
control, not shown), TCam-2, NCCIT and NT2D1 cells 
did not show this activity (Figure 2B). To assess the 
specificity of the effect of c-MET inhibitor PF-04217903 
on HGF-mediated activities, we treated MDCK cells with 
HGF+PF-04217903 and obtained total inhibition of the 
HGF-induced scatter activity. The scoring profile of the 
scatter activity of different doses of HGF and different 
doses of PF-04217903 is provided in Supplementary 
Figure 1.
The absence of HGF expression and secretion 
was expected due to the origin of these cellular lines. 
Considering that all these (T)GCT cell lines, grow as 
epithelial sheets, we evaluated the scatter activity of HGF 
on all (T)GCT cell lines, but observed no HGF-induced 
cell dispersion in any of the (T)GCT lines considered. The 
lack of HGF expression and secretion in these cells let us to 
use the HGF as a stimulating factor in different functional 
experiments, mimicking the testicular microenvironment 
in which this factor is commonly available.
HGF administration increases NT2D1 
proliferation, but does not affect TCam-2 and 
NCCIT cell growth
In the light of the results reported above, we evaluated 
different aspects of HGF activity on (T)GCT cells, starting 
from the well-known capability of this factor to promote 
cell proliferation. We cultured cells in the absence and in the 
presence of HGF for 24, 48 and 72 h. As shown in Figure 
3A, HGF administration does not significantly modify the 
numbers of TCam-2 and NCCIT cells compared with the 
control samples, at all analyzed times, even though in NCCIT 
cells we observed a positive trend after HGF stimulation. 
In NT2D1 cells, HGF promotes cell proliferation starting 
from 24 h of culture. This increase becomes statistically 
significant after 48 and 72 h. To assess the specificity of 
HGF activity on proliferation, we treated NT2D1 cells with 
the c-MET selective inhibitor PF-04217903 under the same 
experimental conditions. The PF-04217903 completely 
abrogates the HGF-induced effect on cell proliferation both 
48 and 72 h of culture (Figure 3A, Supplementary Figure 
5). PF-04217903 does not exert any effect on cell viability 
(dead cells: 3,57% ± 0,08 vs 3,67% ± 0,29 control vs PF-
04217903 respectively). To further investigate the HGF 
effect on NT2D1 cell proliferation, we performed a cell cycle 
FACS-based analysis. Cell starvation let us synchronize 
NT2D1 cellular cycle (68,8% ± 0,6 cells in G1 phase after 
16 h starvation). After 48 h of HGF administration, that is, 
the culture time at which the cell number increase becomes 
statistically significant, we found a higher percentage of 
cells in G2/M phase committed to mitosis compared with 
the control samples (Figure 3B). The co-administration of 
HGF and c-MET inhibitor reverts the increased percentage 
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Figure 1: c-MET expression in (T)GCT cell lines. (A) c-MET gene copy number in TCam-2, NCCIT and NT2D1 cell lines in 
interphasic nuclei and metaphases spread. Multiple copies of c-MET gene in TCam-2 and NT2D1 cells were detected. (B) c-MET qPCR in 
TCam-2, NCCIT and NT2D1 cell lines cultured in medium containing 10% FBS. A higher expression level in c-MET in TCam-2 respect 
to the other two cell lines was detected (b vs a p < 0.05). Quantitative sample value was normalized for the expression of HPRT1. MCF-
10 cells were used as positive control (C) Western blot analysis of c-MET protein in TCam-2, NCCIT and NT2D1 cell lines cultured in 
medium containing 10% FBS. Two different bands, corresponding to the protein precursor (190 KDa band) and the mature full length 
β-chain (145 KDa band), were detected. Densitometric analysis of the 145 KDa bands, normalized versus β-actin, is reported (b vs a 
p < 0.05). MCF-10 cells were used as positive control. (D) Confocal microscopy analysis of c-MET subcellular distribution observed by 
immunofluorescence in TCam-2, NCCIT and NT2D1 cells cultured in medium containing 10% FBS. Representative images of the optical 
spatial series, withdrawn at nuclear level, have been reported. A plasma membrane signal (arrows) and a cytoplasmic diffused signal are 
detectable in all the cells. NCCIT cells show a double population: one c-MET-positive and the other c-MET-negative. FITC signal merged 
with TO-PRO3 staining is reported. The images in the upper panel are lower magnification (scale bar 35 µm), whereas the images in the 
lower panel are higher magnification of the field in the dotted square (scale bar19 µm). All experiments were performed at least in triplicate 
and reported as mean ± SEM.
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of cells in G2/M phase induced by HGF, demonstrating the 
specificity of this response (Figure 3B, Supplementary Figure 
5). For a deeper exploration of the molecular mechanism 
of this biological process activated by HGF in NT2D1 cell 
line, we analyzed the expression level of the cyclin B gene 
(CCNB1), a key regulator of G2/M transition. We performed 
a time-course experiment followed by real time PCR assay 
and found that HGF up-regulates CCNB1 gene starting from 
24 h of culture (Figure 3C, Supplementary Figure 5). At 
the same culture time, we treated cells with PF-04217903 
alone and with HGF+PF-04217903. As shown in Figure 
3C, we observed that in HGF+PF-0421790-treated cells 
CCNB1 expression is comparable to the control level. The 
CCNB1 gene up-regulation after 24 h of HGF administration 
indicates that the HGF action occurs early, but that the 
duration of the phases of the cycle is prolonged due to the 
low FBS concentration (2%) at which these experiments 
were performed. This is the probable reason why we 
observed a significant difference in the numbers of cells only 
after 48 h of culture and not at earlier culture times. Since 
CCNB1 gene up-regulation is a cyclic event, we prolonged 
the time-course experiments and obtained another peak 
Figure 2: HGF expression in (T)GCT cell lines. (A) RT-PCR of HGF expression in TCam-2, NCCIT and NT2D1 cell lines. No 
band for HGF cDNA amplicon was detected in all the cell lines. Human colon fibroblast-derived cDNA was used as positive control, 
whereas SKOV-3 cDNA and water alone were used as negative controls. The evaluation of GAPDH expression was used as loading 
control. (B) Scatter activity assay of TCam-2, NCCIT and NT2D1 conditioned media on MDCK colonies. Cluster morphology of un-
stimulated MDCK or stimulated with conditioned media of TCam-2, NCCIT and NT2D1 were reported. No scatter activity was observed 
in MDCK cells stimulated with GCT cell line conditioned media. All experiments were performed at least in triplicate and reported as 
mean ± SEM. (scale bar: 500 µm).
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Figure 3: Proliferation assays after HGF treatment in TGCT cell lines. (A) Cell count of TCam-2, NCCIT and NT2D1 
cultured in medium containing 2% FCS with or without (Control condition) HGF treatment, for 24–48 and 72 h of culture. An increase 
in cell number in NT2D1 has been observed after 48 and 72 h of stimulation (*p < 0.05). C-MET inhibition by PF-04217903 abrogates 
the HGF induced cell number increase. No significant increase in cell number has been observed in the other cell lines at any culture time 
investigated. (B) Cell cycle FACS analysis on NT2D1 cells in Control condition and after 48 h of HGF stimulation. A significant increase 
of cells in G2/M phase (%) in HGF stimulated samples has been reported (b vs a p < 0.05 p < 0.05). c-MET inhibition by PF-04217903 
abrogates the HGF-induced effect. In the left part of the panel the graphical representation of cell cycle profile is reported. In the right 
part the graphical representation of cell percentage in the different phases of cell cycle is shown. (C) Left part of the panel: time course 
analysis followed by real-time PCR of CCNB1 gene on NT2D1 cell after HGF administration. A significant increase in CCNB1 gene 
expression level is observable after 24 and 54 h of stimulation (*p < 0.05). Right part of the panel: real-time PCR of CCNB1 gene in control 
condition and after HGF, PF-04217903, HGF+PF-04217903 stimulation on 24 h cultured NT2D1. PF-04217903 treatment abrogates the 
HGF induced effect. All experiments were performed at least in triplicate and reported as mean ± SEM.
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of CCNB1 mRNA, although less sharp, at 54 h post-HGF 
administration (Figure 3C). This observation let us conclude 
that the HGF is still able to promote cell proliferation in 
NT2D1 cells even at this culture time. This result is in line 
with the reported maintenance of the cell number increase 72 
h after HGF administration.
HGF acts as chemo-attractant for NCCIT and 
NT2D1 cells
To better characterize the role of c-MET proto-
oncogene in seminoma and non-seminoma cancer 
progression, we investigated the capability of HGF to 
act as a chemo-attractant on the TGCT cell lines. We 
performed a Boyden chamber migration assay using HGF 
molecule in the lower chamber. Our results demonstrate 
that HGF does not significantly modify cell migration in 
TCam-2 cells. In contrast, HGF increases cell migration in 
NCCIT and NT2D1 cell lines (Figure 4A, Supplementary 
Figures 2 and 6). To abrogate the molecular gradient, HGF 
was added to both the upper and lower chambers. In this 
experimental condition, NCCIT and NT2D1 cell migration 
is comparable to the control (Figure 4B, Supplementary 
Figures 2, 6). Our data confirm that HGF acts as a chemo-
attractant for these cell lines. Since HGF is mainly 
expressed by interstitial/connective cells, its chemo-tactic 
activity on these tumor cell lines is relevant and indicates 
a potential HGF role in the chemo-attraction of these cells 
in the interstitial compartment during their escape from the 
tubular compartment, i.e., the transition from to GCNIS to 
invasive growth.
c-MET activation increases NT2D1 cell 
capability of invasion
We decided to investigate another aspect of 
tumorigenesis such as cell invasion. We performed an 
invasion assay using Matrigel basement-coated chambers. 
Cells were cultured on Matrigel layer and treated with 
HGF, PF-04217903 or both factors for 24 h. We found that 
HGF treatment significantly modulates the capability of 
invasion of NT2D1 cells (Figure 4E), whereas in TCam-2 
(Figure 4C) and NCCIT (Figure 4D) cells HGF treatment 
does not modify cell behavior in terms of invasive potential 
(Supplementary Figure 3). Experiments performed to 
verify the specificity of this response in NT2D1 cells 
with the co-administration of HGF+PF-04217903 show a 
reversion of the HGF-induced effect. PF-04217903 alone 
does not modify the invasive capability of NT2D1 cells 
(Figure 4E, Supplementary Figure 3). Next, we tested the 
modulation of proteolytic enzymes of extracellular matrix, 
such as urokinase plasminogen activator (uPA) (Figure 
5A–5C) and metalloproteinases 2 and 9 (MMP-2/MMP-
9) (Figure 6A–6C) in cell conditioned-media. The uPA 
activity at 24 h and 72 h of culture increases with HGF 
treatment only in NT2D1 cells (Figure 5, Supplementary 
Figure 4). Additionally, MMP-2 and MMP-9 activities 
are increased in this cell line (Figure 6C, Supplementary 
Figure 4). Treatment with HGF+PF-04217903 in NT2D1 
cells reverted the HGF effect on uPA and MMP-2/
MMP-9 activity (Figures 5–6, Supplementary Figures 4, 
and 6). Based on these results, we performed the 
Matrigel invasion assay in NT2D1 cells using a 
MMPs inhibitor, GM6001, for the same culture time. 
We observed that the co-administration of HGF with 
GM6001 reverted the HGF effect on cell invasion 
(Figure 6D), thus confirming that HGF-induced invasive 
potential is metalloprotease-dependent (Supplementary 
Figure 3).
HGF administration modulates c-MET activity, 
expression and availability in NT2D1 cells
It is well known that c-MET signaling cascade starts 
with phosphorylation events in the intracellular domain 
of the receptor. Since we observed biological effects upon 
HGF stimulation mainly in NT2D1 cell line, we evaluated 
the phosphorylation rate of c-MET protein by performing 
c-MET immunoprecipitation followed by p-Tyr blot only in 
this cell line. As shown in Figure 7A, after 6 h of treatment 
we observed receptor phosphorylation in HGF-stimulated 
samples, whereas after 24 h no more c-MET phosphorylation 
was observed (Figure 7A). Next, we investigated if HGF 
stimulation could modulate c-MET expression. Cells were 
treated with HGF for different periods of time (3, 6, 12, 18, 
24, and 48 h). After 12 and 18 h, by qRT-PCR assay, we 
observed an up-regulation of the c-MET gene expression 
level in HGF-treated samples compared with the control cells 
(Figure 7B, Supplementary Figure 5). Surprisingly, western 
blot analysis of full-length c-MET protein showed a decrease 
in HGF-stimulated samples, compared with the control, at 
all culture times considered (Figure 7C, Supplementary 
Figure 5). The results obtained by western blot analysis were 
confirmed by immunofluorescence experiments (Figure 7D), 
in which a decrease of c-MET membrane positive signal after 
HGF administration is evident, even though c-MET receptor 
never disappears from the plasma membrane of these cells. 
These apparently conflicting results, could be explained by 
the well-known c-MET pathway activation, which triggers 
the turnover of c-MET protein as a consequence of the ligand-
mediated endocytosis [48–50]. According to this hypothesis, 
the up-regulation of c-MET mRNA observed at 12 and 
18 h after HGF administration could represent a mechanism 
of compensation for the turnover of this membrane receptor. 
Alternatively, it could be hypothesized that the increase 
in c-MET mRNA levels is translated by NT2D1 cells into 
c-MET soluble isoforms or some truncated isoforms that the 
western blot and immunofluorescence analyses cannot reveal 
under these experimental conditions. Further investigations 
are needed to clarify this point.
We treated cells with c-MET inhibitor PF-04217903 
alone or with HGF for the same culture times; c-MET 
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inhibitor does not affect protein expression, but the 
co-administration of HGF+PF-04217903 reverts the 
HGF-dependent effect, and c-MET protein level appears 
comparable with the control samples (Figure 7C, 
Supplementary Figure 5).
C-MET immunoreactivity in TGCT samples
The c-MET immunoreactivity in 150 tissue samples 
from the different histological components (GCNIS, 
SE, EC, YST, CHC and TE) was studied, using c-MET 
immunohistochemistry (IHC) on tissue microarrays 
(TMAs). The staining was scored, and the results are 
shown in Table 1. GCNIS has membranous staining 
for c-MET, in some cases combined with weak nuclear 
staining; cytoplasmic staining is not observed. Seminoma 
has a weaker membranous staining, a weak diffuse 
cytoplasmic staining pattern and stain-negative nuclei. It is 
worth mentioning that GCNIS and SE cells contain a large 
amount of glycogen, which pushes cellular components to 
Figure 4: Boyden chamber and Matrigel invasion assays after HGF treatment in (T)GCT cell lines. (A) Chemotactic 
activity of HGF on TCam-2, NCCIT and NT2D1 after 5 h of chemo-attraction. A significant increase in polarized migration has been 
observed, compared with the negative control (serum free medium + 0.1% BSA), in NCCIT and NT2D1 cell lines (*p < 0.05) whereas no 
modulation in TCam-2 was observed. 1% FBS was used as chemo-attractant positive control. (B) Abrogation of HGF gradient prevents the 
polarized migration in NCCIT and NT2D1 cells. TCam-2 (C), NCCIT (D) and NT2D1 (E) invasion assay in control condition (medium + 
2% FBS + 0.1%BSA) and after 24 h of HGF stimulation. No significant increase has been observed in (C) and (D), whereas a significant 
increase has been reported in (E) (*p < 0.05). c-MET inhibition by PF-04217903 abrogates the HGF-induced increase of invasion in NT2D1 
cell line. All experiments were performed at least in triplicate and reported as mean ± SEM.
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Figure 5: uPA activity in (T)GCT cell line conditioned media after HGF stimulation. Densitometric analysis of casein-gel 
zymographies of TCam-2 (A), NCCIT (B) and NT2D1 (C) conditioned media, evaluating uPA activity in control condition (medium 
containing 2% FBS) and after 24–48–72 h of HGF stimulation. No significant increase has been observed in (A) and (B) in uPA activity, at 
all the analysed culture times. A significant increase has been reported in uPA activity on NT2D1 cell line (C) (*p < 0.05). C-MET inhibition 
by PF-04217903 abrogates the HGF-induced increase of uPA activity in NT2D1 cells. All experiments were performed at least in triplicate 
and reported as mean ± SEM.
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Figure 6: MMPs activity in (T)GCT cell line conditioned media after HGF stimulation. Densitometric analysis of gelatin-
gel zymographies of TCam-2 (A), NCCIT (B) and NT2D1 (C) conditioned media evaluating MMP activity in control condition (medium 
containing 2% FBS) and after 24-48-72 h of HGF stimulation. No significant increase has been observed in (A) and (B) in MMP activity, 
at all the analysed culture times. A significant increase has been reported in MMP activity on NT2D1 cell line (C) (*p < 0.05). C-MET 
inhibition by PF-04217903 abrogates the HGF increase of MMP activity in NT2D1 cells. (D) Effect of MMP inhibition on NT2D1 Matrigel 
invasion assay. MMP inhibition abrogates HGF-dependent invasive behaviour of NT2D1 cells. All experiments were performed at least 
in triplicate and reported as mean ± SEM.
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Figure 7: c-MET phosphorylation, expression, availability and distribution pattern in NT2D1 cells after HGF 
stimulation. (A) Immunoprecipitation of c-MET protein followed by p-Tyr blot in Control condition (2%FBS medium)and after 6 h 
and 24 h HGF stimulated NT2D1. c-MET receptor phosphorylation has been observed after 6 h stimulation, whereas no phosphorylation 
is reportable after 24 h. (B) Time-course analysis followed by real-time PCR of c-Met gene on NT2D1 cell after HGF administration. 
A significant increase in c-Met gene expression level is observable after 12–18 h of stimulation (*p < 0.05). (C) Western blot analysis 
of c-MET protein at time 0 of culture, as well as in control condition and 8, 12, 18, 24 and 48 h after HGF stimulation. A decrease of 
c-MET bioavailability has been detected in all the culture times considered (*p < 0.05). Upper part of the panel: Western blotting detected 
bands are reported. Lower part of the panel: densitometric analysis of the bands, normalized versus β-actin, are reported. (D) c-MET 
immunofluorescence in control condition and after 6, 18, 24 and 48 h after HGF stimulation. All experiments were performed at least in 
triplicate and reported as mean ± SEM (scale bar: 50 µM).
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the periphery of the cell. This phenomenon may explain 
the lack of visible cytoplasmic staining in SE and GCNIS 
cells. Moreover, the Sertoli cells surrounding the GCNIS 
cells also have membranous staining for c-MET, making 
it difficult to assess the contribution of the two cell 
types to the membranous staining of GCNIS cells in the 
spermatogonial niche. 
Embryonal carcinoma cells have stronger 
membranous and cytoplasmic staining than seminoma and 
GCNIS, particularly in necrotic areas and at the luminal 
surface of tubular structures of embryonal carcinoma. The 
nuclei of embryonal carcinoma are stain-negative. The 
strongest expression of c-MET was found in teratoma 
(all epithelial components), in epithelial components of 
yolk sac tumor, and in the cytotrophoblastic component 
of choriocarcinoma. These components show strong 
membranous and cytoplasmic staining. The non-epithelial 
component of yolk sac tumor shows weak membranous 
and cytoplasmic staining; syncytiotrophoblast only has 
a weak cytoplasmic expression (Figure 8). Next, we 
assessed if c-MET immunoreactivity observed in TMA 
section was representative of the whole-tissue sections of 
these tumors. As expected, in whole-tissue sections, we 
observed a more heterogeneous pattern, but the c-MET 
distribution was essentially similar to that seen in the TMA. 
The impact of the presence of c-MET on the origin and 
further progression of (T)GCTs, based on these results, 
remains to be determined, although some conclusions 
can be drawn. The transition from a solely membranous 
localization to a combined membranous and cytoplasmic 
staining in seminoma and various non-seminomatous 
elements is intriguing. The unique nuclear staining in the 
GCNIS cells is of interest as well, although it is unclarified 
so far. It is clear that the possible histological diversity of 
(T)GCTs is not directly reflected by a differential staining 
pattern for c-MET. This diversity is at least associated 
with the lineage of differentiation, which is demonstrated 
by the membranous presence in the cytotrophoblast of 
choriocarcinoma and the absence in the syncytiotrophoblast 
component. 
Concluding remarks
Herein, we demonstrate that:
- c-MET gene appears duplicated in TCam-2 (four 
copies) and NT2D1 (three copies) cells, as part of a likely 
whole-genome duplication, whereas NCCIT cells show a 
normal c-MET gene copy number, due to a possible gene 
loss. The c-MET mRNA level appears consistent with the 
described genetic alterations. However, the c-MET full-
length protein content appears to be differently regulated 
in these (T)GCT cells, being more abundant in NT2D1 
cells and less abundant in TCam-2 cells. 
- The (T)GCT cell line that expresses highest 
levels of full length c-MET protein, is also the most 
sensitive to HGF administration, as expected. In particular, 
we observed that NT2D1 cells react to HGF by increasing 
their proliferation, polarized migration, and invasion 
trend, whereas TCam-2 cells do not seem to significantly 
respond to HGF, as far as the analyzed parameters are 
concerned. Interestingly, NCCIT cells appear capable of 
migrating in a polarized manner after HGF stimulation, 
whereas the proliferation and invasion assays failed to 
show a statistically significant modulation, although 
there was a positive trend. It is worth highlighting, that 
our immunofluorescence analyses provide evidence that 
the NCCIT cell line consist of a mixed population of 
c-MET-positive and c-MET-negative cells. It is therefore 
conceivable that only a fraction of these cells could 
respond to HGF.
- Since NT2D1 appeared to be the most responsive 
cell line, we studied c-MET phosphorylation, and the 
Table 1: Summary results of c-MET immunoreactivity scoring analyses in TGCT histological samples
Tumor component M C N
GCNIS ++ − +
SE + + −

















TE +++ ++ −
c-MET staining intensities were evaluated separately for nuclear, cytoplasmic and membranous immunoreactivity on a 
scale from - to +++.
M: membranous staining; C: cytoplasmic staining; N: nuclear staining; E: epithelial component; NE: non-epithelial 
component; C: cytotrophoblast; S: syncytiotrophoblast.
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regulation of its expression after HGF treatment. As 
expected, short-term exposure to HGF resulted in tyrosine 
phosphorylation of the full-length c-MET receptor, 
which is a prerequisite of the c-MET pathway activation. 
Interestingly, after HGF exposure, NT2D1 cells showed 
a lesser bioavailability of the c-MET receptor, strongly 
indicating that the activation of the c-MET pathway 
triggers the turnover of c-MET protein, due to the 
ligand-mediated endocytosis [48–50]. According to this 
hypothesis, a transient up-regulation of c-MET mRNA, 
occurs to compensate for the turnover of this membrane 
receptor.
- In line with the in vitro results, 
immunohistochemical c-MET analysis of GCNIS and 
seminoma lesions, showed a clear but weak membranous 
immunoreactivity. Embryonal carcinoma cells have 
stronger, mainly membranous staining. Notably, 
in all EC-derived (i.e., differentiated) components 
Figure 8: c-MET immunoreactivity in TGCT histological samples. Representative images of c-MET immunohistochemistry 
on GCNIS (A), Seminoma (B), Embryonal Carcinoma (C), Yolk Sac Tumour (D), Choriocarcinoma (E) and Teratoma (F) samples. The 
highest c-MET immunoreactivity was observed in the epithelial components of Yolk Sac Tumour, Choriocarcinoma and Teratoma.
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(choriocarcinoma, yolk sac tumor and teratoma) the 
highest c-MET immunoreactivity was found in epithelial 
components, irrespective of their aggressiveness, i.e., 
invasive behavior. A possible role of c-MET up-regulation 
in malignant behavior of TGCT, suggested by our in vitro 
findings, requires further investigation.
In conclusion, the results reported herein shed 
new light on TGCT biology opening new perspectives 
for a deeper investigation of the HGF/c-MET system in 
these pathologies, possibly allowing the identification of 
patients at low/high risk of progression. Additionally, the 
presence of c-MET protein in these cancer lesions could 




TCam-2 seminoma cells [46, 51, 52], kindly 
provided by Prof. Claudio Sette (in 2009), were cultured 
in RPMI 1640 (Sigma-Aldrich, cat. R8758) supplemented 
with Fetal Bovine Serum (FBS Gibco, cat. 10270) and 
penicillin/streptomycin (Sigma-Aldrich, cat. P0781). 
NCCIT (of a primary mediastinal Type II GCT origin) and 
NT2D1 cell lines were purchased from the ATCC (in 2015) 
and cultured in DMEM (Sigma-Aldrich, cat. D6546), 
supplemented with FBS, L-glutamine (Sigma-Aldrich, cat. 
G7513) and penicillin/streptomycin. SKOV-3 and MCF-10 
cell lines were cultured in RPMI and DMEM respectively, 
supplemented with 10% FBS, L-glutamine and penicillin/
streptomycin. All cell lines were used from 15 to 35 
passages from the first establishment of the cell lines.
The treated cells received 40 ng/ml of HGF (human 
recombinant HGF; R&D Systems, cat. 294-HG), 50 µM of 
c-MET selective inhibitor PF-04217903 (Sigma-Aldrich, 
cat. SML0263), or 50 µM MMP inhibitor GM6001 
(Calbiochem/Millipore, cat. 364205). The PF-04217903 
toxicity was evaluated by trypan blue exclusion test. We 
tested different concentrations of PF-04217903 (5-10-20-
50 µM) as suggested in the literature (Zou et al., 2012). 
MMP inhibitor GM6001 was used as previously described 
in Ferranti et al., 2012.
Primary human colon fibroblasts (HF), kindly 
provided by Dr. Alessandra Cucina (in 2015), and MDCK 
cells, purchased from the ATCC (in 1998), were cultured 
in DMEM supplemented with 10% FBS, L-glutamine 
(Sigma-Aldrich, cat. G7513)and penicillin/streptomycin 
and used from 5 to 10 passages. Mycoplasma testing was 
routinely done with the N-GARDE Mycoplasma PCR 
Reagent set (EuroClone, cat. EMK090020). The last 
mycoplasma testing was done in July 2017.
FISH analysis
Cells cultured in medium+ 10% FBS were 
trypsinized and harvested for the fluorescence in situ 
hybridization (FISH) experiment according to standard 
cytogenetic procedures. FISH analyses were performed 
on interphase nuclei and metaphase spreads using the 
MET locus-specific identifier (LSI) specific probe 
(Abbott Molecular/Vysis, cat. 06N05-020) according 
to manufacturer’s instructions, and the cells were 
counterstained with DAPI solution. A minimum of 
10 metaphase spreads and 50 nuclei were analyzed for each 
cell line using a fluorescence microscope (Nikon Eclipse 
E600). Image capture and processing were performed using 
the Genikon software (Nikon).
RNA isolation, RT-PCR and qRT-PCR analyses
Cells cultured in medium+ 10% FBS were harvested 
and RNA was extracted using phenol-chloroform 
(TriReagent, Sigma-Aldrich, cat. T-9424). Two micrograms 
of RNA were reverse-transcribed using the M-MLV 
Reverse Transcriptase kit (Invitrogen, cat. 28025-013). 
The semi-quantitative PCR analysis for HGF (Fw 
primer: TCCATGATAGCCACACGAACAC; Rv primer: 
AGCGTACCTCTGGATTGCTT) was carried out in a 
reaction mixture containing 1 unit of Taq DNA polymerase 
(Genedirex, cat. MB101-0500). The cycle parameters for 
HGF were as follows: 45 sec at 94° C, 45 sec at 61° C, and 
1 min at 72° C for 25 cycles. HF cDNA was used as positive 
control and GAPDH (Fw: CTTTTGCGTCGCCAG; 
Rv: TTGATGGCAACAATATCCAC) was used as a 
loading control. The 100 bp DNA ladder (GeneDirex, cat. 
DM001-R500) was used as molecular weight marker for 
amplicons loaded onto agarose gels.
Real-time PCR was performed using the ABI 
PRISM 7500 SDS (Life Technologies-Applied 
Biosystems, USA), the FluoCycle II™ SYBR® Master Mix 
2X (EuroClone, cat. ERD002250BIM) (thermal profile: 
5 min at 95° C for 1 cycle, 15 sec at 95° C for 45 cycles, 
60 sec at 60° C for fluorescent acquisition) and pre-
designed SYBR Green Primers (Sigma-Aldrich) for c-MET 
(Fw primer: AGACACATTTCAATTGGTGG; Rv primer: 
GTAACTGAAGATGCTTGTCTC) and CCNB1 genes 
(Fw primer: GACACCAACTCTACAACATTAC; Rv 
primer: GTCCTTGATTTACCATGACTAC). Quantitative 
sample values were normalized to the expression of 
HPRT1mRNA(Fw primer: TGCAGACTTTGCTTTCCTT 
GGTCAGG; Rv primer: 5′-CCAACACTTCGTGGGG 
TCCTTTTCA) and β2M (Fw primer: AAGGACTGGTC 
TTTCTATCTC; Rv primer: GATCCCACTTAACTATC 
TTGG). The relative level for each gene was calculated 
using the 2−ΔΔCt method [53] and the standard curve 
method.
Protein isolation, immunoprecipitation and 
western blotting assays
Cells were homogenized in RIPA buffer (Sigma-
Aldrich, cat. 0278) containing inhibitors of proteases and 
phosphatases (Roche, cat. 04693124001 and 04906837001 
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respectively). The protein content was determined 
using the BCA protein assay (Pierce, cat. 23221). For 
immunoprecipitation experiments, 250 µg of protein 
extracts was pre-cleared with the True Blot Anti-Rabbit 
Ig IP Beads (Rockland, cat. 00-8800-25) and then rotated 
overnight. at 4° C with rabbit anti-c-MET antibody (Cell 
Signaling Technology, 1:50, cat. 4560). lmmunocomplexes 
were collected using the True Blot Anti-Rabbit Ig IP Beads 
after rotation for 5 h at 4° C.
For western blotting assay, proteins and IP 
immunocomplexes were re-suspended in boiling 
Laemmli buffer under reducing conditions and then 
separated on 7% SDS–PAGE. The proteins were 
electro-transferred to nitrocellulose membrane (Protran, 
cod. 10 401 196). Non-specific antibody bindings was 
blocked by incubation with 5% BSA (Sigma-Aldrich, 
cat. A2153) in TBS-T buffer (20 mMTris, pH 7,6, 
150 mM NaCl/0,1%Tween-20). Then, the membranes 
were incubated with rabbit anti-c-MET (Cell Signaling 
Technology, 1:500, cat. 4560), rabbit anti-c-MET D1C2 
(Cell Signaling, 1:2000, cat.8198), mouse anti-pTyr clone 
4G10 (Millipore, 1:500, cat. 05-321), mouse anti-β-actin 
(1:1000, Sigma-Aldrich, cat. A5441), and mouse anti-α-
tubulin (Sigma-Aldrich, 1:1000, cat. T5168) antibodies 
for 16 hours at 4° C, followed by incubation with the 
appropriate HRP- (Amersham Bioscience, 1:3000, 
cat. NA9340V) or AP-conjugated secondary antibody 
(Sigma-Aldrich 1:3000, cat. A-4312). Immunocomplexes 
were detected using western blot chemiluminescent 
reagents (ECL western blotting detection reagent, 
Euroclone, cat. EMP011005 or CDP-star, PerkinElmer, 
cat. NEL602001KT) following the manufacturer’s 
instructions. The membrane images were acquired 
and analyzed by the ChemiDoc XRS with Image Lab 
software (Bio-Rad Laboratories). The Page Ruler Plus 
Prestained Protein Ladder and Precision Plus Protein All 
Blue Standards (Bio-Rad Laboratories) have been used as 
molecular weight markers.
Immunofluorescence analysis
Cells cultured for 24 h in 10% FBS (Figure 1), or at 
different culture times in 2% FBS with or without HGF, on 
ibidi slides (µ-Slide 8 well, ibidi, cat. 80826) were fixed in 
4%paraformaldehyde in PBS (pH 7.4) at 4° C for 10 min. 
Then, cells were permeabilized in PBS/1% BSA/0.1% 
Triton for 3 h, and incubated overnight with mouse anti-
c-MET antibody (mouse monoclonal, Novocastra, 1:50, 
cat. NCL-cMET). Cells were incubated for 1 hour and 
30 minutes with a FITC-conjugated goat anti-mouse 
IgE (Santa Cruz, 1:80, cat. sc-2082). TO-PRO3 iodide 
fluorescent dye 642/661 (1:5000 in PBS, Invitrogen, cat. 
T3605) was used for nuclei staining. As a negative control, 
the primary antibody was omitted. Immunofluorescence 
experiments were analyzed under a Leica Confocal 
Microscope (Laser Scanning TCS SP2 equipped with Kr/
Ar and He/Ne lasers) by performing optical spatial series 
with a step size of 2 µm.
Scatter activity assay
The scatter activity of TGCT cell culture media, 
obtained after 72 h incubation, was measured on colonies 
of MDCK cells, as previously described [54]. As 
positive controls, HGF- (10 to 60 ng/ml) or human colon 
fibroblast-conditioned media (not shown) were added. The 
HGF concentration of 40 ng/ml is the lowest that triggers 
the 100% of scatter activity of MDCK cells. To test the 
specificity of HGF action, PF-04217903 (5–10–20–50 µM) 
was used. The concentration of 50 µM inhibited 100% of 
scatter activity induced by HGF (Supplementary Figure 1).
Cell proliferation assay
(T)GCT cell lines were cultured in 12-well plates. 
After 8 h, they were starved for 16 h under serum-free 
conditions and then cultured in medium containing 2% FBS 
and HGF for 24, 48 and 72 h. PF-04217903 was also used 
alone or in combination with HGF. After indicated culture 
times, cells were trypsinized, harvested and counted.
Cell cycle FACS analysis
Cells were plated and after 8 h they were maintained 
under serum-free conditions for 16 h, to synchronize 
the cellular cycle. Then, cells were cultured for 48 h in 
the absence or in the presence of HGF, PF-04217903 or 
both factors in 2% FBS. The cells were recovered, fixed 
overnight in 70% EtOH at 4° C and stained with propidium 
iodide (50 µg/mL)/RNase (100 U/mL) solution (Sigma-
Aldrich, cat. P4864 and R6513 respectively) for at least 
3 h. The cell suspensions were analyzed with an Epics 
XL Flow Cytometer (Beckman Coulter). The data were 
analyzed with the FCS Express 5.1 software (De Novo).
Boyden chamber assay
Chemotaxic migration of cells was assayed 
using a polycarbonate filter (pore size, 8 µm, Whatman 
International, cat. 150446) positioned in Boyden chambers 
(Neuro-Probe, Gaithersburg, MD, USA). Cells were 
starved for 16 h under serum-free conditions and then 
5 × 104 cells/well were added to the upper chamber, 
whereas in the lower chamber, HGF or 1% FBS (as 
positive control) were added as chemo-attractants. 
To abolish HGF gradient, the factor was added both 
to the upper and the lower chambers. After 5 h, the 
polycarbonate filters were harvested, cells on the upper 
surface were mechanically removed, filters were fixed 
with paraformaldehyde 4% in PBS (pH 7.4) at 4° C, and 
stained with Diff Quick solution (DADE, cat. 130832). 
The results are reported as the fold increases.
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Matrigel invasion assay
TGCT cell invasion was assayed using chambers 
coated with Matrigel (Basement Membrane Matrix 
Growth Factor Reduced, BD Biosciences, cat. 354483). 
The cells (2,5 × 104/well) were cultured on Matrigel layer 
in medium containing HGF, PF-04217903 or both factors 
in 2% FBS. After 24 h, cells on the upper surface were 
mechanically removed, Matrigel layer containing invading 
cells was fixed with paraformaldehyde (4%, w/v) and 
stained with Diff Quick solution. Four chamber fields 
were photographed, the average number ± SEM of cells 
per field was calculated and reported as the fold increase. 
MMP inhibition was evaluated only in NT2D1 cells. The 
cells cultured on Matrigel layer were treated with GM6001 
alone or in combinations with HGF and then processed as 
described above.
Gel zymography
All TGCT cell lines were cultured for 8 h, serum-
starved for 16 h and then treated with HGF, PF-04217903 
or both factors in 2% FBS for 24, 48 and 72 h. For uPA 
zymography, equal amounts of conditioned media were 
separated under non-reducing conditions in a 10% SDS-
PAGE. The gel was washed twice in 2.5% Triton X-100 
(Sigma-Aldrich, cat. X-100) and then placed on a casein-
agar layer containing human plasminogen as a substrate 
(Sigma-Aldrich, cat. P7999). Gelatinolytic activity of 
conditioned media was assayed as previously described 
[55]. Briefly, 20 µl aliquots of conditioned media and 
cell extracts were fractionated by 10%SDS-PAGE in the 
presence of 0.1% gelatin under non-reducing conditions. 
Following gel electrophoresis, the gels were washed twice 
in 2.5% TritonX-100 for 30 min at room temperature to 
remove SDS. The gels were incubated at 37°C overnight 
in substrate buffer, stained with 0.5% Coomassie Brilliant 
Blue R250 and de-stained in 30% methanol and 10% 
glacial acetic acid (vol/vol). Precision Plus Protein All 
Blue Standards (Bio-Rad Laboratories) have been used 
as molecular weight markers. Densitometric analysis of 
bands was performed using the ImageJ software. Mean ± 
SEM are reported.
Patient samples
Multiple Tissue Micro-Arrays (TMA) were 
investigated, each including primary TGCTs of pure and 
mixed histology. The samples were obtained prior to 
possible systemic therapy. Representative areas, identified 
by both morphological characterization as well as additional 
immunohistochemical staining (including OCT3/4, 
SOX17, SOX2, CD30, AFP and hCG), were selected by 
an experienced pathologist (JWO). These specifically 
identified various histological elements, including GCNIS, 
seminoma, and the various types of non-seminomas, i.e., 
embryonal carcinoma, yolk sac tumor and choriocarcinoma. 
Use of tissue samples remaining after diagnosis for scientific 
reasons was approved by the Medical Ethical Committee 
(MEC) of the Erasmus MC Rotterdam (The Netherlands), 
permission 02.981. This included the permission to use the 
secondary tissue without further consent. Samples were 
used according to the “Code for Proper Secondary Use of 
Human Tissue in The Netherlands” developed by the Dutch 
Federation of Medical Scientific Societies (FMWV (Version 
2002, update 2011)).
C-MET immunohistochemical staining of TMA 
sections and whole tissue sections
Tissue slides were deparaffinized and rehydrated. 
Endogenous peroxidase activity was inactivated in 3% 
H2O2 for 5 min. Subsequently, the slides were subjected 
to antigen retrieval procedure by heating them under high 
pressure up to 1.2 bar in Tris-EGTA buffer (0.01 M Tris, 
0.001 M EGTA, pH 9.0). Endogenous biotin was blocked 
using the Avidin/Biotin Blocking kit (Vector Laboratories 
Ltd; cod. SP-2001). Slides were incubated overnight at 
4° C with the primary rabbit c-MET (D1C2) antibody 
(Cell Signaling, 1:100, cat. 8198). After washing in PBS-
Tween 1%, the slides were incubated for 30 min at room 
temperature with the secondary biotinylated polyclonal 
anti-rabbit antibody (1:150; Dako cod. E0431), and the 
signal was amplified using the VECTASTAIN Elite 
ABC system (Vector Laboratories Ltd, cod. PK-6100). 
Finally, horseradish peroxidase activity was visualized 
with 3, 3′-diaminobenzidine (Dako, cod. K3468) prepared 
following the manufacturer›s instructions. Nuclei were 
stained with hematoxylin solution. Staining intensities 
were evaluated separately for nuclear, cytoplasmic 
and membranous immunoreactivity on a scale from - 
to +++. Two observers (JWO and KCS) assessed the 
immunoreactivity scores.
Statistical analysis
All quantitative data are presented as the 
mean ± standard error (SEM). Student’s t-test and an 
ANOVA for multi-group comparison were carried out. All 
experiments were performed at least in triplicate, and the 
significance level was fixed at a p value < 0.05.
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